Tag Archives: BioPlus

May, 2016

  • 3 May

    Turning Failure into Success

    Hepatitis C treatment, just a few years ago, consisted of only a small handful of treatment options. Any patient who failed treatment was simply out of luck. Today, the treatment landscape has expanded to include multiple different direct-acting antiviral choices. This means a world of difference for patients. It is …

April, 2016

  • 20 April

    The Changing Face of Liver Cancer

    Hepatitis C infections get a lot of bad press when it comes to liver cancer. While it is true that hepatitis C is a significant risk factor for liver cancer, there is another risk factor that is even more risky: metabolic disorders. In fact, new research just found that metabolic …

March, 2016

  • 29 March

    Texting For Meds

    Could better medication adherence be just a “text away”? According to a new analysis taking a closer look at several previous studies about adherence, when patients receive text reminders about their medication, adherence rates go up. Way up. Looking at medication adherence data from approximately 2,700 patients with chronic diseases, …

  • 16 March

    Patient Tipping Point

    Patients face a tipping point when it comes to out-of-pocket costs. When patients’ share of health care costs reach a certain threshold, patients are more likely to skip refills of medications or fail to get their prescriptions filled in the first place. Most recently, this was demonstrated in a study …

  • 9 March

    Smoothing the Path

    Medication adherence continues to be a challenge for the health care community. Successful treatment of disease simply cannot occur if patients are not adherent to medications. In addition, non-adherence leads to systemic waste. For example, up to 10% of all money spent on health care is attributed to avoidable health …

February, 2016

  • 24 February

    Turning Patients into Partners

    Education opens minds. For patients, education often means the difference between adherence and non-adherence, which in turn determines the effectiveness of treatment. More than ever before, the health care community understands that an active partnership between patients and their health care team can empower patients and lead to better outcomes. …

  • 9 February

    New Hepatitis C Combo On the Way

    Another once-daily pill is on-track for approval by the U.S. Food and Drug Administration (FDA) for the treatment of hepatitis C, adding to the growing number of treatment options for this life-threatening disease. This time, it’s a combination of Sovaldi® (sofosbuvir) with a new NS5A inhibitor called velpatasvir from Gilead …

  • 2 February

    Meet Zepatier

    There’s a new option in the treatment of hepatitis C, with the U.S. Food and Drug Administration (FDA) approving Merck’s Zepatier™ (elbasvir and grazoprevir) just a few days ago on January 28, 2015. This medication’s entry to the treatment field came on an accelerated track with the FDA granting it …

January, 2016

  • 27 January

    Cost and Value

    Where does the true value of cancer treatment lie? Oncology experts grapple with this important question, with one of the more recent people to chime in being Robert C. Young, M.D., of RCY Medicine in Philadelphia, in an essay in a recent issue of the New England Journal of Medicine. Dr. …

  • 19 January

    The True Cost

    Infection with the hepatitis C virus (HCV) remains a leading cause of liver cancer in the United States. Treatments now available for HCV can cure upwards of 90% of patients; however, the high price tag of these HCV treatments can serve as an obstacle to these medications reaching all infected …